查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1781937

双特异性抗体市场，按药物类型、按适应症、按配销通路、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Bispecific Antibodies Market, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年双特异性抗体市场规模价值 109.9209 亿美元，2025 年至 2032 年的复合年增长率为 40.10%。

双特异性抗体市场-市场动态

增加FDA批准以推动市场需求

双特异性抗体疗法的认可不断增加，推动了市场扩张。美国食品药物管理局（FDA）在2022年至2024年间批准了6种双特异性抗体，反映出监管机构对创新癌症治疗的支持力道不断增加。此外，日益加重的癌症负担也加速了对先进免疫疗法的需求，促使人们投资于双特异性抗体等标靶疗法。然而，复杂的生产流程和高昂的开发成本仍然是双特异性抗体市场成长的挑战。相反，政府对癌症研究的资助正在拓展创新潜力，这为全球双特异性抗体市场提供了巨大的成长机会。

双特异性抗体市场－关键见解

根据我们的研究分析师的分析，预计全球市场在预测期内（2025-2032 年）的年复合成长率约为 40.10%。

根据药物类型细分，免疫球蛋白 G 预计在 2024 年占据最大市场份额

根据适应症细分，癌症是 2024 年的主要适应症

按地区划分，北美是 2024 年最大的收入来源

双特异性抗体市场-細項分析：

全球双特异性抗体市场根据药物类型、适应症、配销通路和地区进行细分。

根据适应症，市场分为三类：发炎和自体免疫疾病、癌症和其他。预计在预测期内，癌症领域将占据主要市场份额。这主要得益于全球癌症负担的不断增加，以及双特异性抗体在靶向肿瘤细胞和活化免疫反应方面取得的巨大临床成功。

根据配销通路，市场分为四类：药局、零售药局、医院药局和线上药局。预计医院药局将占据主要市场份额。这是因为双特异性抗体主要用于癌症和自体免疫疾病等复杂疾病，这些疾病需要专门的给药、监测和住院护理。

双特异性抗体市场—地理洞察

在预测期内，北美地区预计将占据全球双特异性抗体市场的主要份额，这得益于先进的医疗保健基础设施、强大的研发投资以及美国 FDA 等机构的早期监管批准。

另一方面，由于癌症盛行率上升、临床试验活动增加、医疗保健覆盖范围扩大以及中国、印度和韩国等国家生物製药投资不断增长，预计亚太地区将以最快的速度成长。

双特异性抗体市场-竞争格局：

标靶免疫疗法需求的不断增长加剧了竞争，促使各公司采取以创新、临床开发和监管批准为重点的策略。各公司正大力投资研发，以增强双特异性抗体的剂型、改善安全性并提高其在癌症和自体免疫疗法中的疗效。策略合作、授权交易以及向新兴市场的扩张也是关键策略。此外，各公司正在利用先进的平台和专有技术来加速研发管线的进展，并在快速发展的治疗领域中确保长期竞争优势。

最新动态：

2025年3月，三优生物推出73款双特异性抗体参考产品，涵盖已获准和临床阶段的药物，旨在透过双靶点结合支持药物开发并应对挑战，克服单靶点治疗中出现的抗药性等限制。

2025 年 4 月，Invenra Inc. 宣布推出其 B-Body Express(TM) 抗体表现服务，使生物技术和製药公司能够快速从合作伙伴序列中获得高纯度、经过验证的双特异性抗体，从而以速度和先进的技术加速临床前研究。

目录

第 1 章：双特异性抗体市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 双特异性抗体市场（依药物类型）
    • 双特异性抗体市场片段（按适应症）
    • 双特异性抗体市场片段（依配销通路）
    • 双特异性抗体市场（按国家/地区）
    • 双特异性抗体市场按地区划分
  • 竞争洞察

第三章：双特异性抗体主要市场趋势

  • 双特异性抗体市场驱动因素
    • 市场驱动因素的影响分析
  • 双特异性抗体市场限制
    • 市场限制的影响分析
  • 双特异性抗体的市场机会
  • 双特异性抗体市场未来趋势

第四章：双特异性抗体产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：双特异性抗体市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：双特异性抗体市场格局

  • 2024年双特异性抗体市占分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：双特异性抗体市场－依药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 免疫球蛋白G
    • 非免疫球蛋白G

第 8 章：双特异性抗体市场 - 按适应症

  • 概述
    • 按适应症细分市场占有率分析
    • 发炎与自体免疫疾病
    • 癌症
    • 其他的

第九章：双特异性抗体市场－按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 药局
    • 零售药局
    • 医院药房
    • 网路药局

第 10 章：双特异性抗体市场-依地域划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美双特异性抗体主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（依药品类型）
    • 北美市场规模及预测（按适应症）
    • 北美市场规模及预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲双特异性抗体主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（依药品类型）
    • 欧洲市场规模及预测（按适应症）
    • 欧洲市场规模及预测（按配销通路）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区双特异性抗体主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依药品类型）
    • 亚太地区市场规模及预测（依适应症）
    • 亚太地区市场规模及预测（按配销通路）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲双特异性抗体主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按药物类型）
    • 拉丁美洲市场规模及预测（按适应症）
    • 拉丁美洲市场规模及预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲双特异性抗体主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依药物类型）
    • MEA 市场规模及预测（依适应症）
    • MEA 市场规模及预测（依配销通路）
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 11 章：双特异性抗体产业关键供应商分析

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Amgen
    • Genentech
    • Akeso, Inc.
    • Taisho Pharmaceutical
    • Janssen
    • Immunocore
    • Adimab, Innovent Biologics, Inc.
    • AstraZeneca
    • Affimed GmbH
    • Xencor
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Regeneron Pharmaceuticals Inc.
    • Pieris Pharmaceuticals, Inc.
    • Eli Lilly
    • Mereo BioPharma Group plc
    • Merus
    • MacroGenics, Inc.
    • Sobi, TG Therapeutics Inc.
    • Genmab A/S
    • Alteogen
    • Emergent BioSolutions Inc.
    • Novartis AG
    • Astellas Pharma Inc.
    • Celgene Corporation
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5388

REPORT HIGHLIGHT

Bispecific antibodies market size was valued at US$ 10,992.09 Million in 2024, expanding at a CAGR of 40.10% from 2025 to 2032.

Bispecific antibodies are engineered proteins designed to recognize and bind to two different antigens simultaneously. Unlike traditional monoclonal antibodies that target a single molecule, bispecific antibodies can engage two targets, such as a cancer cell and a T-cell, enhancing immune response and therapeutic precision. This dual-targeting ability makes them highly effective in treating complex diseases like cancer, autoimmune disorders, and infectious diseases, offering improved outcomes and reduced off-target effects.

Bispecific Antibodies Market- Market Dynamics

Increasing FDA approvals to propel market demand

The growing approval of bispecific therapies is driving market expansion, with the U.S. FDA approving 6 bispecific antibodies between 2022 and 2024, reflecting rising regulatory support for innovative cancer treatments. Besides, increasing cancer burden is accelerating demand for advanced immunotherapies, prompting investment in targeted therapeutics like bispecific antibodies. However, complex manufacturing processes and the high development costs continue to challenge bispecific antibodies market growth. On the contrary, government funding for cancer research is expanding innovation potential, which is providing massive growth opportunities for the global bispecific antibodies market.

Bispecific Antibodies Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 40.10% over the forecast period (2025-2032)

Based on Drug Type segmentation, immunoglobulin G was predicted to show maximum market share in the year 2024

Based on Indication segmentation, cancer was the leading Indication in 2024

On the basis of region, North America was the leading revenue generator in 2024

Bispecific Antibodies Market- Segmentation Analysis:

The Global Bispecific Antibodies Market is segmented on the basis of Drug Type, Indication, Distribution Channel, and Region.

The market is divided into three categories based on Indication: inflammatory & autoimmune disorder, cancer, and others. The cancer segment is expected to hold the major market share during the forecast period. This is primarily driven by the growing global cancer burden and the strong clinical success of bispecific antibodies in targeting tumor cells and activating immune responses.

The market is divided into four categories based on Distribution Channel: drug stores, retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies sector is expected to hold the major market share. This is because bispecific antibodies are primarily used in complex conditions like cancer and autoimmune diseases, which require specialized administration, monitoring, and inpatient care.

Bispecific Antibodies Market- Geographical Insights

The North America region is expected to hold the major market share in the global bispecific antibodies market during the forecast period, driven by advanced healthcare infrastructure, strong R&D investments, and early regulatory approvals by agencies like the U.S. FDA.

On the other hand, the Asia-Pacific region is projected to grow at the fastest rate, owing to rising cancer prevalence, increasing clinical trial activity, expanding healthcare access, and growing biopharmaceutical investments in countries such as China, India, and South Korea.

Bispecific Antibodies Market- Competitive Landscape:

Growing demand for targeted immunotherapies is intensifying competition, pushing companies to adopt strategies focused on innovation, clinical development, and regulatory approvals. Firms are investing heavily in R&D to enhance bispecific antibody formats, improve safety profiles, and increase efficacy in cancer and autoimmune treatments. Strategic collaborations, licensing deals, and expansion into emerging markets are also key approaches. Additionally, players are leveraging advanced platforms and proprietary technologies to accelerate pipeline progress and secure long-term competitive advantages in a rapidly evolving therapeutic landscape.

Recent Developments:

In March 2025, SanyouBio launched 73 bispecific antibody reference products covering approved and clinical-stage drugs, aiming to support drug development and address challenges by enabling dual-target binding to overcome limitations like resistance seen in single-target therapies.

In April 2025, Invenra Inc. announced the launch of its B-Body Express(TM) Antibody Expression service, allowing biotech and pharma companies rapid access to high-purity, validated bispecific antibodies from partner sequences, accelerating preclinical research with speed and advanced technology.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BISPECIFIC ANTIBODIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen
  • Genentech
  • Akeso, Inc.
  • Taisho Pharmaceutical
  • Janssen
  • Immunocore
  • Adimab, Innovent Biologics, Inc.
  • AstraZeneca
  • Affimed GmbH
  • Xencor
  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Regeneron Pharmaceuticals Inc.
  • Pieris Pharmaceuticals, Inc.
  • Eli Lilly
  • Mereo BioPharma Group plc
  • Merus
  • MacroGenics, Inc.
  • Sobi, TG Therapeutics Inc.
  • Genmab A/S
  • Alteogen
  • Emergent BioSolutions Inc.
  • Novartis AG
  • Astellas Pharma Inc.
  • Celgene Corporation
  • Others

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Immunoglobulin G
  • Non-Immunoglobulin G

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Inflammatory & Autoimmune Disorder
  • Cancer
  • Others

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Drug Stores
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

GLOBAL BISPECIFIC ANTIBODIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bispecific Antibodies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bispecific Antibodies Market Snippet by Drug Type
    • 2.1.2. Bispecific Antibodies Market Snippet by Indication
    • 2.1.3. Bispecific Antibodies Market Snippet by Distribution Channel
    • 2.1.4. Bispecific Antibodies Market Snippet by Country
    • 2.1.5. Bispecific Antibodies Market Snippet by Region
  • 2.2. Competitive Insights

3. Bispecific Antibodies Key Market Trends

  • 3.1. Bispecific Antibodies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bispecific Antibodies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bispecific Antibodies Market Opportunities
  • 3.4. Bispecific Antibodies Market Future Trends

4. Bispecific Antibodies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bispecific Antibodies Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Bispecific Antibodies Market Landscape

  • 6.1. Bispecific Antibodies Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bispecific Antibodies Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
    • 7.1.2. Immunoglobulin G
    • 7.1.3. Non-immunoglobulin G

8. Bispecific Antibodies Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 8.1.2. Inflammatory & Autoimmune Disorder
    • 8.1.3. Cancer
    • 8.1.4. Others

9. Bispecific Antibodies Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 9.1.2. Drug Stores
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Hospital Pharmacies
    • 9.1.5. Online Pharmacies

10. Bispecific Antibodies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bispecific Antibodies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bispecific Antibodies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bispecific Antibodies Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Bispecific Antibodies Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Bispecific Antibodies Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bispecific Antibodies Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Amgen
    • 11.2.2. Genentech
    • 11.2.3. Akeso, Inc.
    • 11.2.4. Taisho Pharmaceutical
    • 11.2.5. Janssen
    • 11.2.6. Immunocore
    • 11.2.7. Adimab, Innovent Biologics, Inc.
    • 11.2.8. AstraZeneca
    • 11.2.9. Affimed GmbH
    • 11.2.10. Xencor
    • 11.2.11. F. Hoffmann-La Roche Ltd.
    • 11.2.12. Sanofi
    • 11.2.13. Regeneron Pharmaceuticals Inc.
    • 11.2.14. Pieris Pharmaceuticals, Inc.
    • 11.2.15. Eli Lilly
    • 11.2.16. Mereo BioPharma Group plc
    • 11.2.17. Merus
    • 11.2.18. MacroGenics, Inc.
    • 11.2.19. Sobi, TG Therapeutics Inc.
    • 11.2.20. Genmab A/S
    • 11.2.21. Alteogen
    • 11.2.22. Emergent BioSolutions Inc.
    • 11.2.23. Novartis AG
    • 11.2.24. Astellas Pharma Inc.
    • 11.2.25. Celgene Corporation
    • 11.2.26. Others

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us